1. Optimised nickase- and nuclease-based prime editing in human and mouse cells. https://academic.oup.com/nar/article/49/18/10785/6371974
2. Large deletions induced by Cas9 cleavage. https://www.nature.com/articles/s41586-018-0380-z
3. Targeted deletion of an entire chromosome using CRISPR/Cas9. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30257-5
4. Versatile single-step-assembly CRISPR/Cas9 vectors for dual gRNA expression. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187236
5. CRISPR applications for Duchenne muscular dystrophy: from animal models to potential therapies. https://wires.onlinelibrary.wiley.com/doi/full/10.1002/wsbm.1580
6. Expanding the RNA-Guided Endonuclease Toolkit for Mouse Genome Editing. https://www.liebertpub.com/doi/abs/10.1089/crispr.2018.0050
7. CRISPR-mediated megabase-scale transgene de-duplication to generate a functional single-copy full-length humanised DMD mouse model. https://link.springer.com/article/10.1186/s12915-024-02008-7
8. Optimal SpCas9- and SaCas9-mediated gene editing by enhancing gRNA transcript levels through scaffold poly-T tract reduction. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11317-2
9. CRISPR-mediated generation and comprehensive phenotyping of Duchenne Muscular Dystrophy mouse models. https://link.springer.com/article/10.1186/s44330-024-00019-y
Gene Editing Therapeutics
The University of Adelaide, Adelaide SA 5000, Australia
Email: contact@geneeditingtx.com
Copyright © 2025 Gene Editing Therapeutics - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.